THERAPEUTIC FOR THE PREVENTION AND/OR TREATMENT OF WEIGHT GAIN AND/OR DIABETES
    3.
    发明申请
    THERAPEUTIC FOR THE PREVENTION AND/OR TREATMENT OF WEIGHT GAIN AND/OR DIABETES 审中-公开
    用于预防和/或治疗体重增加和/或糖尿病的治疗

    公开(公告)号:WO2018089602A1

    公开(公告)日:2018-05-17

    申请号:PCT/US2017/060809

    申请日:2017-11-09

    Abstract: Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.

    Abstract translation: 本公开的实施方案包括用于治疗其中GLP-1增加对个体有益的医学病症的组合物和方法。 在具体的实施方案中,本公开涉及能够在具有医学病症(例如II型糖尿病或肥胖症)的个体中诱导GLP-1产生的某些肽。 在其他情况下,个体不是肥胖或超重,而是为了减少脂肪重量而提供肽。

    COMPOSICIÓN FARMACÉUTICA PARA PREVENIR, TRATAR Y CURAR LA ROSÁCEA QUE COMPRENDE BABA DE CARACOL, MANZANILLA Y PROPÓLEO
    7.
    发明申请
    COMPOSICIÓN FARMACÉUTICA PARA PREVENIR, TRATAR Y CURAR LA ROSÁCEA QUE COMPRENDE BABA DE CARACOL, MANZANILLA Y PROPÓLEO 审中-公开
    用于预防,治疗和治疗罗非鱼的药物组合物,包括SNAIL SLIME,CAMOMILE和PROPOLIS

    公开(公告)号:WO2016054757A1

    公开(公告)日:2016-04-14

    申请号:PCT/CL2014/000054

    申请日:2014-10-17

    Applicant: MUCIDERM S.A.

    Abstract: La presente invención se refiere a una composición farmacéutica conformada por baba de caracol Helix aspersa müller (Cryptophalus aspersus ) (20% a 50%), extracto de manzanilla (1-4%), propóleo (1-4%) y aditivos y/o excipientes farmacéuticamente aceptables para formar una formulación de viscosidad baja, intermedia o alta (10 a 1000 Pa-s). Dicha composición en forma de loción, jabón, crema o gel, embebido en tela tipo gasa en forma de parche para ser aplicada sobre lesiones de los diversos tipos de rosácea. La composición puede contener además extractos naturales tales como extracto de caléndula, miel y aceites vegetales. Se reivindica además el procedimiento de obtención de la composición y su uso para preparar un medicamento o dispositivo para prevenir, tratar o curar lesiones derivadas de la rosácea, en la piel del rostro o del cuerpo.

    Abstract translation: 本发明涉及一种药用组合物,其包括蜗牛粘液(Asixia mens)(20%至50%),甘菊提取物(1-4%),蜂胶(1-4%)和药学上可接受的赋形剂和/或 用于形成低粘度(中等)或高粘度(10〜1000Pa·s)的配方的添加剂。 所述组合物为洗剂,肥皂,乳膏或凝胶的形式,其以石膏形式包埋在纱布型织物中,其可应用于由不同类型的红斑痤疮引起的损伤。 组合物还可以含有天然提取物如万寿菊提取物,蜂蜜和植物油。 本发明还涉及用于制备用于预防,治疗或治愈由酒渣鼻引起的损伤的面部或身体的皮肤的药物或装置的组合物的制备方法及其用途。

    OINTMENT FOR THE TREATMENT OF HEMORRHOIDAL DISEASE
    8.
    发明申请
    OINTMENT FOR THE TREATMENT OF HEMORRHOIDAL DISEASE 审中-公开
    治疗霍乱病的药物

    公开(公告)号:WO2015174876A1

    公开(公告)日:2015-11-19

    申请号:PCT/RO2015/000009

    申请日:2015-04-24

    Abstract: The invention relates to an ointment for the treatment of internal haemorrhoids, able to avoid the advanced stages of the disease and the need for surgical intervention on long term. The ointment for the treatment of hemorrhoidal disease, according to the invention, especially for treating internal hemorrhoids grades I and II comprise axungia (animal fat), lanolin, white vaseline, camphor, calcium carbonate, eucalyptus oil, ethanol (ethyl alcohol) and preservatives. The ointment implementation and testing were structured in two phases, namely: a product design phase and a test phase (the testing was performed at the Faculty of Medicine and Pharmacy of the University "Dunarea de Jos"). In the first phase it was conducted the biochemical characterization of the microbiological and functional product and in the second phase it was conducted the selection of the group of patients, the clinical and para-clinical assessment of patients, in order to exclude possible pathologies caused or contributing to hemorrhoidal disease.

    Abstract translation: 本发明涉及用于治疗痔疮的软膏,其能够避免疾病的晚期阶段和长期需要手术干预。 根据本发明,用于治疗痔疮疾病的软膏,特别是用于治疗I型和II型痔疮的内痔,包括轴突(动物脂肪),羊毛脂,白凡士林,樟脑,碳酸钙,桉树油,乙醇(乙醇)和防腐剂 。 软膏实施和测试分两个阶段进行,分别是:产品设计阶段和测试阶段(测试在University of Medicine and Pharmacy of University“Dunarea de Jos”)进行。 在第一阶段进行微生物和功能性产品的生物化学表征,第二阶段进行了患者组的选择,患者的临床和临床评估,以排除引起的可能的病理或 有助于痔疮疾病。

    NOVEL RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH INCREASED DURATION OF EFFECT
    10.
    发明申请
    NOVEL RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH INCREASED DURATION OF EFFECT 审中-公开
    新的重组离子神经毒素具有增加的作用时间

    公开(公告)号:WO2015132004A1

    公开(公告)日:2015-09-11

    申请号:PCT/EP2015/000489

    申请日:2015-03-04

    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.

    Abstract translation: 本发明涉及显示出增加的作用持续时间的新型重组梭菌神经毒素和制备这种重组梭菌神经毒素的方法。 这些新型的重组梭菌神经毒素包括无规卷曲结构域,并且所述方法包括以下步骤:将编码无规卷曲结构域的核酸序列插入到编码亲本梭菌神经毒素的核酸序列中,并且重组核酸序列的表达包括 随机线圈域编码序列在宿主细胞中。 本发明还涉及用于这些方法的新型重组单链前体梭菌神经毒素,编码这种重组单链前体梭菌神经毒素的核酸序列,以及包含具有增加的效果持续时间的重组梭菌神经毒素的药物组合物。

Patent Agency Ranking